SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
SPRC stock price ended at $0.95 on 星期一, after dropping 5.94%
On the latest trading day Jan 26, 2026, the stock price of SPRC fell by 5.94%, dropping from $1.00 to $0.95. During the session, the stock saw a volatility of 11.11%, with prices oscillating between a daily low of $0.90 and a high of $1.00. On the latest trading day, the trading volume for SPRC rose by 623.3K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 716.1K shares were traded, with a market value of approximately $3.1M.